Keywords: Boehringer Ingelheim, Viramune, Flomax, Impax, Patents, USA

Boehringer Ingelheim launches co-pay rebate program for Viramune in USA; settles with Impax over Flomax

Article | 07 October 2009

Independent German drugmaker Boehringer Ingelheim’s US subsidiary has launched the Viramune (nevirapine) tablets/oral suspension Co-Pay Savings Program, a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Boehringer Ingelheim

Astellas Pharma

Go to company listing

Related Drugs

Nevirapine

Viramune

Flomax

Tamsulosin Hydrochloride

Nystatin

Go to drug listing